Aimed at improving quality of life and extending the ocular healthspan of patients with chronic blinding diseases. The round was led by ClavystBio, with participation from Polaris Partners and SEEDS.

Cirrus will use the proceeds from the seed financing to advance its lead program into IND-enabling studies. This novel adeno-associated virus (AAV) ocular gene therapy is designed to reverse a recently identified and validated underlying cause of dry age-related macular degeneration (dry AMD): loss of IRAK-M protein, a key immune regulator expressed in retinal cells.